Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luden's Echinacea Throat Drops Are Not Dietary Supplements, FDA Says

This article was originally published in The Tan Sheet

Executive Summary

FDA continues to hold the position that throat or cough drops cannot be classified as dietary supplements, according to a Nov. 4 "courtesy" letter to Hershey Foods recently made available by the agency. Luden's Throat Drops/Herbal Echinacea Supplement with echinacea, rose hips and vitamin C "does not appear to meet the statutory definition of a dietary supplement...and therefore, can not be marketed as a dietary supplement," FDA says (1see box, p. 8). Hershey launched the extension to the Luden's line in August (2see story, p. 6).

You may also be interested in...



Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel